Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma by Kai Tai Derek Yeung, PhD, FRCS, Sacheen Kumar, PhD, FRCS, David Cunningham, MD, FRCP, FMedSci, OBE, Long R. Jiao, MD, FRCS, Ricky Harminder Bhogal, PhD, FRCS

“…We approach BR/LA PDAC using chemotherapy followed by selective CRT to the primary site of disease where either the surgical margin remains radiologically threatened following chemotherapy or as a further downstaging treatment. …”
Get full text

Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Canc... by Hisao Imai, Keita Mori, Nodoka Watase, Sakae Fujimoto, Kyoichi Kaira, Masanobu Yamada, Koichi Minato

“…The effects of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies in patients with small-cell lung cancer (SCLC). …”
Get full text

SarkoLife: quality of life in patients undergoing multimodal soft tissue sarcoma treatment by Sebastian Hoffmann, Tabea Hoffmann, Vlatko Potkrajcic, Christoph K. W. Deinzer, Katrin Benzler, Lars Zender, Adrien Daigeler, Johannes Tobias Thiel

“…The primary emphasis was on comparing three distinct modalities: Radiation, Chemotherapy and Surgery. The data were analysed performing one-way ANOVA. …”
Get full text

An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients by Nai-si Huang, Xiao Shi, Bo-wen Lei, Wen-jun Wei, Zhong-wu Lu, Peng-cheng Yu, Yu Wang, Qing-hai Ji, Yu-long Wang

“…By directly comparing eight treatment modalities, we found that surgery+radiotherapy RT±chemotherapy was the most effective treatment strategy. surgery+chemotherapy and RT+chemotherapy had comparable results (hazard ratio HR=1.461, 95% confidential interval (CI): 0.843-2.531, P=0.177). …”
Get full text

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC by Mandy Jongbloed, MD, Valentina Bartolomeo, MD, Martina Bortolot, MD, Shahan Darwesh, MD, Jarno W.J. Huijs, MD, Safiye Dursun, MD, Juliette Degens, MD, PhD, Ben E.E.M. van den Borne, MD, PhD, Maggy Youssef-El Soud, MD, PhD, Marcel Westenend, MD, PhD, Cordula Pitz, MD, PhD, Dirk K.M. De Ruysscher, MD, PhD, Lizza E.L. Hendriks, MD, PhD

“…Results: A total of 416 patients were included, treated with chemotherapy-ICI (n = 138) or chemotherapy-only (n = 278), 319 out of 416 were deemed candidates by multidisciplinary meetings for LRT, whereas 192 (60%) proceeded to LRT. …”
Get full text

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review by Chao Wang, Yunzhuo Dong, Peng Men, Ruixia Zhang, Ying Xiao, Yishan Bu, Yinpeng Qin, Xinran Zhang, Qianqian Dou, Yiheng Yang, Huier Gao, Yi Zhang

“…The incidence of grade 3–5 AEs, infusion-related reactions (IRRs), and infection were higher in the obinutuzumab based chemotherapy group compared to other chemotherapies. …”
Get full text

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients... by Heather L. McArthur, Sara M. Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Qiang Liu, Jane Lowe Meisel, Naoki Niikura, Yeon Hee Park, Gustavo Werutsky, Giampaolo Bianchini, Jay C. Andersen, Robert Kozarski, Nana Rokutanda, Barbara Pistilli, Sibylle Loibl

“…Methods and analysis: Approximately 1728 patients (aged ⩾18 years) will be randomized 1:1 to eight cycles of neoadjuvant Dato-DXd (6 mg/kg intravenously (IV) every 3 weeks (Q3W)) plus durvalumab (1120 mg IV Q3W) followed by nine cycles of adjuvant durvalumab (1120 mg IV Q3W) with or without chemotherapy versus eight cycles of pembrolizumab (200 mg IV Q3W) plus chemotherapy followed by nine cycles of adjuvant pembrolizumab (200 mg IV Q3W) with or without chemotherapy. …”
Get full text

The prevalence and prognostic significance of Sarcopenia and Adipopenia in Pleural Mesothelioma by Andrew C. Kidd, Gordon W. Cowell, Geoffrey A. Martin, Jenny Ferguson, Dean A. Fennell, Matt Evison, Kevin G. Blyth

“…Pre-chemotherapy sarcopenia and adipopenia were defined using validated thresholds, where available or indices <25th percentile. …”
Get full text

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma by Takayuki Ando, Ayumu Hosokawa, Hiroki Yoshita, Akira Ueda, Shinya Kajiura, Hiroshi Mihara, Sohachi Nanjo, Haruka Fujinami, Jun Nishikawa, Kohei Ogawa, Takahiko Nakajima, Johji Imura, Toshiro Sugiyama

“…Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. …”
Get full text

Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center by Noorwati Sutandyo, Ikhwan Rinaldi, Lyana Setiawan, Christine Sugiarto, Yuniar Harris Prayitno

“…Sampling was carried out by taking peripheral blood, which was taken 7–14 days after the patient underwent the 3rd and 6th cycles of chemotherapy or before and 7–14 days following the 3rd cycle of chemotherapy. …”
Get full text

Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center by Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel

“…In the oncology conference a vote for or against chemotherapy was taken on the basis of the conventional criteria for decision-making before the test results were available. …”
Get full text

Umbrella review of adjuvant photodynamic therapy for cholangiocarcinoma palliative treatment by Hanhan Chen, Honglin Li, Huijie Li, Zhen Zhang

“…Adding PDT to stenting or chemotherapy may be more beneficial for long-term efficacy.…”
Get full text

Hemorrhagic Cystitis due to BK Reactivation in a Young Female Treated for Hodgkin-Disease by R. Le Calloch, J. C. Ianotto, C. Berthou, A. Tempescul

“…Complications due to chemotherapy could include viral reactivation due to chronic lymphopenia. …”
Get full text

Severely Disseminated Kaposi Sarcoma after ABO-Incompatible Kidney Transplantation Treated Successfully with Paclitaxel and Gemcitabine Combined with Hemodialysis by Tobias Bomholt, Anders Krarup-Hansen, Martin Egfjord, Søren Schwartz Sørensen, Niels Junker

“…No guidelines for chemotherapy exist in this case and reduced kidney function and impaired immune system complicates the use of systemic chemotherapy in kidney transplant recipients. …”
Get full text

Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia by MAO Mingyi, JIANG Fang, XIANG Yang

“…High-risk patients have a higher risk of resistance to single-agent chemotherapy and require combination chemotherapy. Even worse, there are some high-risk patients who develop resistance to combination chemotherapy or experience recurrence after cure. …”
Get full text

Primary Small-Cell Carcinoma of the Palate with Cushing’s Syndrome: A Case Report by Yingqiu Song, Zhenyu Lin, Lingjuan Chen, Gang Wu

“…The patient was treated with six cycles of chemotherapy consisting of etoposide and cisplatin. After one year, the patient developed bone metastases and Cushing's syndrome, and successfully recovered with subsequent chemotherapy with irinotecan and cisplatin plus radiotherapy. …”
Get full text

Acute Immune-Mediated Thrombocytopenia due to Oxaliplatin and Irinotecan Therapy by Eric L. Tam, Padma L. Draksharam, Jennifer A. Park, Gurinder S. Sidhu

“…We describe a case of a 63-year-old woman with advanced colon cancer and liver metastases who was treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and cetuximab chemotherapy. She tolerated 13 cycles of chemotherapy without any significant hematological side effects, but after the 14th cycle, she developed melena and was admitted for severe thrombocytopenia. …”
Get full text

miR-1247-3p regulation of CCND1 affects chemoresistance in colorectal cancer. by Dequan Wang, Jielian Wang, Fei Yao, Zhufu Xie, Jianze Wu, Huiguang Chen, Qingming Wu

“…The effectiveness of chemotherapy involving 5-fluorouracil and cisplatin (DDP) for the treatment of colorectal cancer (CRC) is often limited due to the emergence of drug resistance. …”
Get full text

In vitro activity of macrolides against Streptococcus pneumoniae and Streptococcus pyogenes in the Russian Federation: “Status praesens” by Kozlov R.S., Ivanchik N.V., Mikotina A.V., Dekhnich A.V.

Get full text

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer by Jie Fu, Jie Fu, Yi-Dan Yan, Xu Wan, Xiao-Fan Sun, Xiao-Fan Sun, Xiu-Mei Ma, Ying-Jie Su

“…Regarding OS, for patients with PD-L1 expression ≥50%, 1%–49% and &lt;1%, camrelizumab + chemotherapy (HR 0.48, 95% CI: 0.21–1.11), cemiplimab + chemotherapy (HR 0.50, 95% CI: 0.32–0.79) and nivolumab + ipilimumab (HR 0.64, 95% CI: 0.51–0.81) were considered optimal treatments. …”
Get full text